rdf:type |
|
lifeskim:mentions |
umls-concept:C0003320,
umls-concept:C0004561,
umls-concept:C0039194,
umls-concept:C0056912,
umls-concept:C0085358,
umls-concept:C0086418,
umls-concept:C0449450,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1706438,
umls-concept:C1749467,
umls-concept:C2698600
|
pubmed:issue |
4
|
pubmed:dateCreated |
2011-2-3
|
pubmed:abstractText |
Naive B lymphocytes are generally thought to be poor APCs, and there is limited knowledge of their role in activation of CD8(+) T cells. In this article, we demonstrate that class I MHC Ag presentation by human naive B cells is enhanced by TLR9 agonists. Purified naive B cells were cultured with or without a TLR9 agonist (CpG oligodeoxynucleotide [ODN] 2006) for 2 d and then assessed for phenotype, endocytic activity, and their ability to induce CD8(+) T cell responses to soluble Ags. CpG ODN enhanced expression of class I MHC and the costimulatory molecule CD86 and increased endocytic activity as determined by uptake of dextran beads. Pretreatment of naive B cells with CpG ODN also enabled presentation of tetanus toxoid to CD8(+) T cells, resulting in CD8(+) T cell cytokine production and granzyme B secretion and proliferation. Likewise, CpG-activated naive B cells showed enhanced ability to cross-present CMV Ag to autologous CD8(+) T cells, resulting in proliferation of CMV-specific CD8(+) T cells. Although resting naive B cells are poor APCs, they can be activated by TLR9 agonists to serve as potent APCs for class I MHC-restricted T cell responses. This novel activity of naive B cells could be exploited for vaccine design.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD86,
http://linkedlifedata.com/resource/pubmed/chemical/CD86 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CpG ODN 2006,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Oligodeoxyribonucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/TLR9 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 9
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1550-6606
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
186
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2080-6
|
pubmed:dateRevised |
2011-10-6
|
pubmed:meshHeading |
pubmed-meshheading:21239717-Adjuvants, Immunologic,
pubmed-meshheading:21239717-Adult,
pubmed-meshheading:21239717-Antigen-Presenting Cells,
pubmed-meshheading:21239717-Antigens, CD86,
pubmed-meshheading:21239717-B-Lymphocyte Subsets,
pubmed-meshheading:21239717-CD8-Positive T-Lymphocytes,
pubmed-meshheading:21239717-Cells, Cultured,
pubmed-meshheading:21239717-Coculture Techniques,
pubmed-meshheading:21239717-Cross-Priming,
pubmed-meshheading:21239717-Endocytosis,
pubmed-meshheading:21239717-G0 Phase,
pubmed-meshheading:21239717-Gene Expression Regulation,
pubmed-meshheading:21239717-Histocompatibility Antigens Class I,
pubmed-meshheading:21239717-Humans,
pubmed-meshheading:21239717-Ligands,
pubmed-meshheading:21239717-Lymphocyte Activation,
pubmed-meshheading:21239717-Oligodeoxyribonucleotides,
pubmed-meshheading:21239717-Solubility,
pubmed-meshheading:21239717-T-Lymphocytes,
pubmed-meshheading:21239717-Toll-Like Receptor 9
|
pubmed:year |
2011
|
pubmed:articleTitle |
Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.
|
pubmed:affiliation |
Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, OH 44106, USA. wei.jiang@case.edu
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|